絞り込み

16376

広告

「elotuzumab」の検索結果

139件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Elotuzumab as a Novel Anti-Myeloma Immunotherapy.

Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.

New Agents in Multiple Myeloma: An Examination of Safety Profiles.

Hematologic Malignancies: Plasma Cell Disorders.

Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.

How is patient care for multiple myeloma advancing?

Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.

Which therapies will move to the front line for multiple myeloma?

Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.

How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis.

Immunotherapy for the treatment of multiple myeloma.

Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.

FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.

A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 hour, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.

Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.

Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.

Immune Therapies in Multiple Myeloma.

Progress and Paradigms in Multiple Myeloma.

Safety issues and managment of toxicities associated with new treatments for multiple myeloma.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
Sort by
※並べ替えは表示に時間がかかります